Days after announcing the first response rates from a Phase I/II trial of CAR T cell therapy AUTO1, Autolus raised $100.8 million in a follow-on offering.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,